IMU 3.77% 5.1¢ imugene limited

Ann: Imugene Presentation to JPMorgan Healthcare Conference, page-70

  1. 2,867 Posts.
    lightbulb Created with Sketch. 11921
    Hi sorest!

    Well - I would say it's because the Pembro combo arm of the trial started later than the monotherapy. So as of 31 Oct there were just fewer Pembro patients in the trial. Only 8 in total, and of those only 6 had reached the point of first scan (Day 42).

    The Pembro trial is still lagging behind the mono trial - because it started later. The Mono trial is now dosing at 3 x 108 in both IT and IV. By contrast the Combo trial is only at 3 x 107 in IT and 1 x 108 in IV.

    It will catch up, of course, once they confirm optimum biologic dose. From the data - the combo patients seem to be doing roughly as well as the monotherapy - but these are still small numbers. What impresses me is how well the mono patients are doing - just on Vaxinia alone. Maybe - over time - the combo arm will generate better results, but who knows? That's why they have both mono and combo arms. We will know when the data tells us....

    Cheers

    Dave
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.1¢
Change
-0.002(3.77%)
Mkt cap ! $376.9M
Open High Low Value Volume
5.2¢ 5.2¢ 5.0¢ $450.9K 8.786M

Buyers (Bids)

No. Vol. Price($)
72 3844468 5.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 1192187 7
View Market Depth
Last trade - 15.16pm 05/07/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.